The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 30 of the 38 sources its claims cite were checked for support.
Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study
Open accessPublished version of a preprint
Abstract
Relapsed or refractory osteosarcoma carries a poor prognosis after standard chemotherapy. We conducted a multicenter, randomized, phase II trial (NCT05277480) to compare apatinib plus ifosfamide/etoposide (IE) with IE alone in patients who had progressed following at least one prior line of chemotherapy. Patients were randomized 2:1 to receive apatinib (500 mg orally once daily) plus IE (ifosfamide 1.8 g/m²/day and etoposide 100 mg/m²/day, days 1–3 every 3 weeks) or IE alone (same doses, days 1–5 every 3 weeks). The primary endpoint was progression-free survival (PFS). Between April 14, 2022, and August 22, 2023, 81 patients were enrolled (53 in apatinib plus IE group and 28 in IE group). After a median follow-up of 19.9 months, the median PFS was 5.5 months (95% confidence interval [CI]: 3.9, 6.4) with apatinib plus IE compared with 3.4 months (95% CI: 1.4, 4.6) with IE (hazard ratio, 0.60; 95% CI: 0.37, 0.98; P = 0.0402). The trial met its pre-specified primary endpoint. These results suggest that apatinib plus IE may improve PFS in relapsed or refractory osteosarcoma, but as a randomized phase II study, the findings are exploratory and require confirmation in phase III trials. In patients with metastatic osteosarcoma who have progressed on first-line chemotherapy, the prognosis is poor. Here, the authors report a phase II randomized clinical trial comparing the combination of apatinib (multi tyrosine kinase inhibitor) and chemotherapy (ifosfamide and etoposide) against chemotherapy alone in patients with relapsed or refractory metastatic osteosarcoma.
Overview
CoChat Summary
TL;DR
In this randomized phase II trial, adding apatinib to ifosfamide/etoposide significantly prolonged progression-free survival versus ifosfamide/etoposide alone in patients with advanced osteosarcoma that had progressed after prior chemotherapy. The authors describe the findings as exploratory and requiring phase III confirmation, with no overall survival benefit observed.
Key findings
- Median PFS was 5.5 months (95% CI 3.9–6.4) with apatinib plus IE versus 3.4 months (95% CI 1.4–4.6) with IE alone (HR 0.60; 95% CI 0.37–0.98; P = 0.0402), meeting the primary endpoint.
- Median OS was 18.1 months (95% CI 13.7–25.2) with apatinib plus IE versus 22.9 months (95% CI 19.3–NE) with IE alone (HR 1.48; 95% CI 0.76–2.89; nominal P = 0.2493).
- ORR was 32.1% versus 25.0% (P = 0.6126), and DCR was 90.6% versus 60.7% (P = 0.0026).
- Grade ≥3 TRAEs occurred in 69.8% of the apatinib plus IE group versus 64.3% of the IE group; SAEs occurred in 11.3% versus 10.7%.
Methods
- Multicenter, randomized, open-label phase II trial conducted at four centers in China (NCT05277480); 81 patients were enrolled 2:1 to apatinib plus IE (n = 53) or IE alone (n = 28).
- Eligible patients were aged 12–65 years with histologically/pathologically confirmed locally advanced or metastatic high-grade osteosarcoma progressing after at least one prior chemotherapy line, measurable by RECIST 1.1.
- Treatment: apatinib 500 mg orally once daily plus ifosfamide 1.8 g/m²/day and etoposide 100 mg/m²/day on days 1–3 every 3 weeks, versus the same ifosfamide/etoposide doses on days 1–5 every 3 weeks. Primary endpoint was investigator-assessed PFS; Kaplan-Meier, log-rank test, and Cox proportional hazards models were used.
Limitations
- The authors state that no biomarker analysis was included, that apatinib plus IE was not compared with apatinib monotherapy or apatinib plus anti-PD-1 therapy, and that the open-label design plus differences in chemotherapy dose intensity may have biased patient-reported QoL assessments.
- The authors also emphasize that this was an exploratory phase II trial: PFS was lower than anticipated, EFS did not reach statistical significance when local therapy was counted as an event (HR 0.64; 95% CI 0.40–1.02; nominal P = 0.0598), and no OS benefit was observed.
- The text makes evident additional limitations: the sample size was small, multiple comparisons were not adjusted for, and protocol-disallowed local therapies occurred in some patients, complicating interpretation of PFS/EFS.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
15 Valid · 0 Not valid · 4 Not checked · 55 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Apatinib, a multi-targeted TKI utilized in the treatment of gastric, non-small cell lung, and esophageal cancers8, has demonstrated efficacy in inhibiting the proliferation, migration, and invasion of osteosarcoma in both preclinical and clinical trials4,6 (Supplementary Table 1).”
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Introduction
What the sources say
- Partly supportedcites [4] Xie, L. et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist 24, e542–e550 (2019). sourceExperimental — accuracy not yet measured
The Introduction reports preclinical apatinib-induced growth inhibition in osteosarcoma, and the Discussion reports tumor shrinkage and a 43.24% objective response rate in this phase II clinical trial (page numbers not provided). The paper does not report that apatinib inhibited osteosarcoma cell migration or invasion, so those parts of the claim are unsupported. (LLM, conf=0.86)
- Partly supportedcites [6] Xie L. et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 8, e000798 (2020). sourceExperimental — accuracy not yet measured
The Background (page unavailable) reports antitumor activity for apatinib in a previous clinical trial of refractory osteosarcoma, including a 43.2% response rate. The References name a preclinical paper on inhibition of osteosarcoma migration and invasion, but this paper does not report that apatinib inhibits proliferation or show that all three cellular effects were demonstrated in both preclinical and clinical trials. (LLM, conf=0.84)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The rationale for combining TKIs with IE, including lenvatinib plus IE, was initially proposed by Gaspar et al.11–13 with the idea of inhibition of angiogenesis may increase uptake of IE into tumor tissue through vascular normalization.”
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Introduction
What the sources say
- Partly supportedcites [11] Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E. & Bautista, F. OLIE, ITCC-082: a phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. Future Oncol. 17, 4249–4261 (2021). sourceExperimental — accuracy not yet measured
The Background & rationale section states that lenvatinib’s inhibition of angiogenesis may increase ifosfamide and etoposide uptake through vascular normalization. It supports the proposed rationale for lenvatinib plus IE, but does not establish that Gaspar et al. initially proposed it or extend that rationale to TKIs generally. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [12] Gaspar, N. et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 22, 1312–1321 (2021). source
- Partly supportedcites [13] Gaspar, N. et al. Lenvatinib plus ifosfamide and etoposide in children and young adults with relapsed osteosarcoma: a phase 2 randomized clinical trial. JAMA Oncol. 10, 1645–1653 (2024). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“local therapies such as radiotherapy for large tumor burdens can significantly delay secondary drug resistance and prolong EFS”
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Discussion
What the sources say
- Partly supportedcites [14] Xie, L. et al. Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: a retrospective study in two centres. Oncol. Lett. 22, 552 (2021). sourceExperimental — accuracy not yet measured
The Discussion (page not provided) reports that 16 of 33 patients receiving apatinib plus ifosfamide and etoposide underwent local radiation or surgery. It explicitly says whether those treatments contributed to prolonged EFS needs clarification; it does not show a significant EFS benefit or that local therapy delayed secondary drug resistance. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the efficacy of TKIs is often compromised by factors such as large tumor volumes, poor performance status, and the axial location of lesions4,5.”
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Introduction
What the sources say
- Partly supportedcites [4] Xie, L. et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist 24, e542–e550 (2019). sourceExperimental — accuracy not yet measured
The Results (page not available) report that the site of target lesions was associated with progression-free survival on apatinib. But the paper does not identify axial location specifically, large tumor volume, or poor performance status as factors compromising TKI efficacy; it calls target-lesion site the only obvious factor influencing progression-free survival in this trial. Its finding in an apatinib trial also does not establish that these factors often compromise TKIs generally. (LLM, conf=0.84)
- Could not verifycites [5] Gaspar, N. et al. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050). ESMO Open 6, 100250 (2021). sourceExperimental — accuracy not yet measured
The Results > Patients tables list performance scores and lesion sites, while Results > Efficacy reports lenvatinib outcomes. Neither section links TKI efficacy to tumor volume, poor performance status, or axial lesion location; searches for those factors and for predictors of efficacy found no such analysis in our copy. Page numbers were not available. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Based on our prior clinical observations, TKI monotherapy appeared insufficient to control extra-pulmonary lesions14.”
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Introduction
What the sources say
- Supportedcites [14] Xie, L. et al. Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: a retrospective study in two centres. Oncol. Lett. 22, 552 (2021). source
The Introduction reports rapid resistance to apatinib in musculoskeletal lesions and identifies progression outside the lung as a challenge during TKI-based treatment. The Discussion likewise says TKIs have short-lived activity against musculoskeletal lesions and other metastases outside the lungs. Page numbers are not available in our copy. (LLM, conf=0.91)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims · 4 with their cited sources checked
Create a free account to see all 74 claims and to verify the 2 references still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 17
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Results > Baseline characteristics of patients
“| Age, years, median (range) | 15.5 (12–46) | 22.5 (12–52) |”
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Results > Baseline characteristics of patients
“| <18 | 29 (54.7) | 15 (53.6) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Results > Safety profiles
“However, neutropenia and thrombocytopenia did not seem to be more severe in the Apa+IE group because the dose of the chemotherapy had been reduced in the combination group (Table 3).”
§ Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study > Results > Safety profiles
“| Platelet count decreased | 39 (73.6) | 21 (39.6) | 15 (53.6) | 8 (28.6) |”
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“Enrollment criteria mandated that the disease be measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) 19 .”
InfluentialAaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359 · cited 2×
“Additionally, clinical trials involving TKIs alone are typically with median PFS ranging from 4 to 6 months accompanied with inevitable development of secondary drug resistance 1 – 5 .”
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02374 · Cited by 268
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
Scott, L. J. (2018) · Drugs · doi:10.1007/s40265-018-0903-9 · Cited by 231 · cited 1×
“Apatinib, a multi-targeted TKI utilized in the treatment of gastric, non-small cell lung, and esophageal cancers 8 , has demonstrated ef fi - cacy in inhibiting the proliferation, migration, and invasion of osteosarcoma in both preclinical and clinical trials 4,6 (Supplementary Table 1).”
Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190
Xie, L., Xu, J., Sun, X., Guo, W., Gu, J., Liu, K., Zheng, B., Ren, T., Huang, Y., Tang, X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000798 · Cited by 145
Self-citationXie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0542 · Cited by 128 · cited 3×
“Apatinib, a multi-targeted TKI utilized in the treatment of gastric, non-small cell lung, and esophageal cancers 8 , has demonstrated ef fi - cacy in inhibiting the proliferation, migration, and invasion of osteosarcoma in both preclinical and clinical trials 4,6 (Supplementary Table 1).”
Self-citationGaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89 · cited 2×
“Our study utilized a lower daily dose of ifosfamide (1.8g/m²/day compared to 3 g/m²/day in ITCC-050 and OLIE/ITCC-082) but extended the chemotherapy regimen to 10 cycles, compared to fi ve cycles in the ITCC-050 and OLIE/ITCC-082 studies 12,13 .”
Cited by
Yu, H., Yuan, X., Li, X., Tong, J., Huang, C., You, X., & Wu, J. (2026) · Neurobiology of Pain · doi:10.1016/j.ynpai.2026.100226
Ricciardi, G., Fiorentino, V., Tralongo, P., Lentini, M., Pepe, L. R., Zuccalà, V., Ballato, M., Giuffrè, G., Ieni, A., Zampogna, B., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1823738 · Cited by 1
Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting
Kotapati, S., Manoharan, M., & Palmerini, E. (2026) · Biomolecules · doi:10.3390/biom16081167 · Cited by 1
“Apatinib plus IE demonstrated a more statistically convincing signal: 65.8% versus 41.6% PFS at 4 months (hazard ratio 0.60; 95% CI 0.37–0.98; p = 0.0402), with a confidence interval excluding 1.0 and qualifying it as a positive study [28].”
Influential
Metadata
- Authors
- Xie, L., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Liu, R., Wang, D., Shao, S., Chen, Z., Pang, Z., Zhou, G., Wu, S., Hua, Y., Hu, H., Wei, R., Yang, Y., Ji, T., Guo, W., & Tang, X.
- Affiliations
- Peking University People's Hospital (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Guo, Wei
- Tang, Xiaodong
- ORCID
- Venue
- Nature Communications
- Published
- 2025-11-25
- Volume
- 16
- Issue
- 1
- Pages
- 10473-10473
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC12647724
- OpenAlex
- W4416631760
- Cited by
- 3
- References
- 19
- Citations by year
- 2026: 3
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Peking University
- Peking University People's Hospital
- National Science and Technology Major Project
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- osteosarcoma, apatinib, ifosfamide, etoposide, metastatic osteosarcoma, tyrosine kinase inhibitors, progression-free survival, second-line chemotherapy, combination chemotherapy
- MeSH terms
- Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Etoposide, Female, Humans, Ifosfamide, Male, Middle Aged, Pyridines, Osteosarcoma, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study. https://app.cochat.ai/papers/10.1038/s41467-025-65467-8
- The paper
- Xie, L., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Liu, R., Wang, D., Shao, S., Chen, Z., Pang, Z., Zhou, G., Wu, S., Hua, Y., Hu, H., Wei, R., Yang, Y., Ji, T., Guo, W., & Tang, X. (2025). Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study. Nature Communications. https://doi.org/10.1038/s41467-025-65467-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.